NASDAQ:OKUR OnKure Therapeutics 3/10/2025 Earnings Report $2.89 -0.04 (-1.37%) Closing price 04/17/2025 04:00 PM EasternExtended Trading$3.05 +0.16 (+5.54%) As of 04/17/2025 05:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Earnings HistoryForecast OnKure Therapeutics EPS ResultsActual EPS-$1.37Consensus EPS -$0.86Beat/MissMissed by -$0.51One Year Ago EPSN/AOnKure Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AOnKure Therapeutics Announcement DetailsQuarterDate3/10/2025TimeAfter Market ClosesConference Call DateN/AConference Call TimeN/AUpcoming EarningsOnKure Therapeutics' next earnings date is estimated for Tuesday, May 6, 2025, based on past reporting schedules. Conference Call ResourcesEarnings HistoryCompany Profile OnKure Therapeutics Earnings HeadlinesOnKure Therapeutics, Inc. Class A Common Stock (OKUR) ChartsApril 16 at 9:21 AM | nasdaq.comOnKure Therapeutics price target lowered to $34 from $40 at H.C. WainwrightMarch 18, 2025 | markets.businessinsider.comWhat to do with your collapsing portfolio…There might be only one way to save your retirement in this volatile time. After watching investors lose $6 trillion in market cap in a matter of DAYS... And after seeing businesses bleeding dry as trade tensions spiral out of control... What the acclaimed “Market Wizard” Larry Benedict — who beat the market by 103% during the 2008 crash — is about to reveal could not only save your retirement from Trump's tariffs…April 18, 2025 | Brownstone Research (Ad)Promising Outlook for OnKure Therapeutics: Strategic Developments and Market Expansion Plans for 2025March 18, 2025 | tipranks.comWill OnKure Therapeutics (NASDAQ:OKUR) Spend Its Cash Wisely?March 12, 2025 | finance.yahoo.comOptimistic Buy Rating for OnKure Therapeutics Driven by Promising OKI-219 Development and Future ProspectsMarch 12, 2025 | tipranks.comSee More OnKure Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like OnKure Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on OnKure Therapeutics and other key companies, straight to your email. Email Address About OnKure TherapeuticsOnKure Therapeutics (NASDAQ:OKUR), Inc. engages in discovering and developing precision medicines that target biologically validated drivers of cancers underserved by available therapies. The company uses a structure and computational chemistry driven drug design platform, committed to improving clinical outcomes for patients by building a robust pipeline of small molecule drugs designed to selectively target specific mutations thought to be key drivers of cancer. It is headquartered in Boulder, CO.View OnKure Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Archer Aviation Unveils NYC Network Ahead of Key Earnings Report3 Reasons to Like the Look of Amazon Ahead of EarningsTesla Stock Eyes Breakout With Earnings on DeckJohnson & Johnson Earnings Were More Good Than Bad—Time to Buy? Why Analysts Boosted United Airlines Stock Ahead of EarningsLamb Weston Stock Rises, Earnings Provide Calm Amidst ChaosIntuitive Machines Gains After Earnings Beat, NASA Missions Ahead Upcoming Earnings Tesla (4/22/2025)Intuitive Surgical (4/22/2025)Verizon Communications (4/22/2025)Canadian National Railway (4/22/2025)Novartis (4/22/2025)RTX (4/22/2025)3M (4/22/2025)Capital One Financial (4/22/2025)General Electric (4/22/2025)Danaher (4/22/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
